184 related articles for article (PubMed ID: 12271881)
1. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac.
Morant SV; Shield MJ; Davey PG; MacDonald TM
Pharmacoepidemiol Drug Saf; 2002; 11(5):393-400. PubMed ID: 12271881
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis.
Kristiansen IS; Kvien TK; Nord E
Arthritis Rheum; 1999 Nov; 42(11):2293-302. PubMed ID: 10555023
[TBL] [Abstract][Full Text] [Related]
3. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.
Al MJ; Michel BC; Rutten FF
Pharmacoeconomics; 1996 Aug; 10(2):141-51. PubMed ID: 10163417
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.
Maetzel A; Ferraz MB; Bombardier C
Arthritis Rheum; 1998 Jan; 41(1):16-25. PubMed ID: 9433865
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
Arthritis Rheum; 2000 Apr; 43(4):917-24. PubMed ID: 10765939
[TBL] [Abstract][Full Text] [Related]
7. [Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
Soto Alvarez J
An Med Interna; 2000 Sep; 17(9):477-84. PubMed ID: 11100534
[TBL] [Abstract][Full Text] [Related]
8. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol.
Goldstein JL; Larson LR; Yamashita BD
Am J Manag Care; 1998 May; 4(5):687-97. PubMed ID: 10179922
[TBL] [Abstract][Full Text] [Related]
9. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.
Rahme E; Pettitt D; LeLorier J
Arthritis Rheum; 2002 Nov; 46(11):3046-54. PubMed ID: 12428249
[TBL] [Abstract][Full Text] [Related]
10. Diclofenac/misoprostol. Pharmacoeconomic implications of therapy.
Plosker GL; Lamb HM
Pharmacoeconomics; 1999 Jul; 16(1):85-98. PubMed ID: 10539124
[TBL] [Abstract][Full Text] [Related]
11. Complications of nonsteroidal antiiflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center.
Bakowsky VS; Hanly JG
J Rheumatol; 1999 Jul; 26(7):1557-63. PubMed ID: 10405945
[TBL] [Abstract][Full Text] [Related]
12. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial.
von Scheele B; Peña B; Wong J; Niculescu L
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii53-9. PubMed ID: 14585918
[TBL] [Abstract][Full Text] [Related]
14. Use of gastroprotection in patients discharged from hospital on nonsteroidal anti-inflammatory drugs.
Coté GA; Norvell JP; Rice JP; Bulsiewicz WJ; Howden CW
Am J Ther; 2008; 15(5):444-9. PubMed ID: 18806520
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
Höer A; Gothe H; Schiffhorst G; Sterzel A; Grass U; Häussler B
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):854-8. PubMed ID: 17323403
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
[TBL] [Abstract][Full Text] [Related]
17. Rheumatologists' adherence to guidelines for misoprostol use in patients at high risk for nonsteroidal antiinflammatory drug gastropathy.
Cibere J; Sibley JT; Haga M
J Rheumatol; 2002 Feb; 29(2):339-46. PubMed ID: 11838854
[TBL] [Abstract][Full Text] [Related]
18. Prescribing rationale and budgetary outcomes associated with the introduction of a combined formulation of diclofenac sodium and misoprostol in Canada.
Sclar DA; Robison LM; Maheu A; Skaer TL
J Int Med Res; 1995; 23(6):439-48. PubMed ID: 8746611
[TBL] [Abstract][Full Text] [Related]
19. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.
Rahme E; Barkun A; Nedjar H; Gaugris S; Watson D
Am J Gastroenterol; 2008 Apr; 103(4):872-82. PubMed ID: 18371130
[TBL] [Abstract][Full Text] [Related]
20. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Joshua FF; Oakley SP; Major GA
Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
